SECsense Logo

Lexaria Bioscience Corp. 8-K Report: Key Financial Insights as of December 31, 2024

$LEXX
Form 8-K
Filed on: 2025-01-03
Source
Lexaria Bioscience Corp. 8-K Report: Key Financial Insights as of December 31, 2024

From the provided financial report excerpt, here are the key pieces of information and insights extracted:

  1. Entity Information:
  • Company Name: Lexaria Bioscience Corp.
  • CIK (Central Index Key): 0001348362
  • SEC File Number: 000-39874
  • Company Address: 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7
  • Phone Number: 250-765-6424
  1. Report Type and Date:
  • Filing Type: 8-K (a form used to report major events)
  • Filing Date: December 31, 2024
  1. Stock Information:
  • Common Stock:
    • Par Value: $0.001 per share
  • Warrants:
    • Warrants to purchase common stock are also mentioned.
  • Stock Symbols:
    • Common Stock: LEXX
    • Warrants: LEXXW
  • Exchange: NASDAQ
  1. Financial Period:
  • The report covers a specific date: December 31, 2024, indicating that it is likely reporting on events or conditions as of that date.
  1. Units and Measures:
  • Financial metrics are reported in USD (US Dollars).
  • There is a reference to measures in terms of shares, but specific quantities or financial values are not detailed in this excerpt.
  1. XBRL Tags:
  • The report utilizes XBRL (eXtensible Business Reporting Language) format for structured data, indicating compliance with SEC filing standards.

Insights:

  • Lexaria Bioscience Corp. is a publicly traded company on NASDAQ, suggesting it has undergone the necessary regulatory processes to offer its shares to the public.
  • The inclusion of warrants indicates potential future dilution of shares, as these financial instruments allow holders to purchase stock at predetermined prices.
  • The report type (8-K) suggests that this filing may be related to a significant corporate event, although the specific nature of that event is not detailed in this snippet.
  • The report is structured to align with US GAAP (Generally Accepted Accounting Principles), which is essential for transparency and comparability in financial reporting.

This information is critical for investors or analysts looking to assess Lexaria Bioscience Corp.'s financial health and market activity as of the end of 2024.